#United States #Chicago #Renibus Therapeutics #RBT-1 #PROTECT Trial

Renibus Therapeutics Highlights Phase 3 PROTECT Trial Data for RBT-1

Renibus Therapeutics® recently made headlines by presenting significant data from their Phase 3 PROTECT trial regarding RBT-1 at the prestigious American Association for Thoracic Surgery (AATS) Annual Meeting, held from May 2-5, 2026, in Chicago, Illinois. This event serves as a crucial platform where leading experts gather to share their latest research and advancements in thoracic surgery.

Overview of RBT-1 and PROTECT Trial

RBT-1 is a novel pharmacologic agent designed to precondition patients before undergoing cardiac surgery. This agent possesses antioxidant and anti-inflammatory properties, aimed at potentially reducing postoperative complications in patients who require cardiopulmonary bypass. The Phase 3 PROTECT study was a randomized, double-blind, placebo-controlled trial that included 433 patients across 34 clinical sites in the U.S. and Canada. The primary focus was on patients undergoing non-emergency coronary artery bypass grafting (CABG) and valve surgeries, who received either RBT-1 or a placebo infusion 24 to 48 hours before their operations.

Although the study did not achieve its primary endpoint, which evaluated a composite of adverse outcomes including death, dialysis-requiring acute kidney injury (AKI), 30-day cardiopulmonary readmissions, and ICU days, the trial revealed valuable insights. Approximately 70% of participants were classified as low-risk, based on the Society of Thoracic Surgeons' risk calculator, which may have complicated the primary analysis and affected the ability to observe significant treatment effects in the overall patient group.

Preliminary Findings and Focused Analysis

While the primary endpoints were not met, post-hoc analyses indicated that RBT-1 may confer advantages for higher-risk patients, particularly those with chronic kidney disease and elevated risk scores. According to Dr. Jeffrey Keyser, Chief Executive Officer of Renibus Therapeutics, although the primary study goal was not achieved, the treatment effect trends observed in riskier demographics suggest a pathway for more targeted studies in the future. He expressed optimism about exploring these trends further, as they could shape the development of RBT-1 into specific populations where the drug may demonstrate a more pronounced effect.

Safety and Tolerability of RBT-1

Importantly, RBT-1 was reported to be generally safe and well-tolerated among participants, with adverse events primarily consisting of photosensitivity and temporary reactions related to the infusion. Significantly, no serious treatment-related events caused delays or cancellations of surgeries, underscoring the safety profile of the drug in a surgical context.

Dr. Michael E. Jessen, Chair of the Department of Cardiovascular Thoracic Surgery at University of Texas Southwestern Medical Center, emphasized the significance of addressing postoperative complications in patients undergoing high-risk cardiac surgeries. He noted that the observed trends for higher-risk populations could justify further investigations into RBT-1's role in mitigating these complications, proposing that a deeper understanding of its efficacy in specific cohorts is warranted.

Future Directions for Renibus Therapeutics

Renibus is poised to continue its efforts in advancing RBT-1, with plans to refine their strategy based on the outcomes of the PROTECT trial. The company seeks to identify the patient populations most likely to benefit from the treatment and intends to pursue further research in these areas.

For those interested in the findings, the full presentation from the AATS meeting is available on Renibus's official website. The continued development of RBT-1 represents a promising advancement for the treatment of patients undergoing cardiac surgery and reflects Renibus Therapeutics's commitment to addressing significant unmet medical needs.

For more details, visit Renibus Therapeutics.